GlassScriptPhysician profile
Archis D Desai
NPI 1396141230
$4,796.26
in general payments reported to CMS, 2019-2025
19 companies · $877 in 2025
The $877 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $57.84 · 2021: $1,547 · 2022: $896 · 2023: $634 · 2024: $661 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,073.61 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $971.61 | 2019-2025 | Spravato |
| Abbvie INC. | $509.14 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $451.28 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $410.65 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $339.34 | 2019-2025 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $246.91 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $180.01 | 2019-2022 | |
| Lundbeck LLC | $126.31 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $100.74 | 2021-2022 | |
| Alkermes, INC. | $83.79 | 2022-2025 | Lybalvi, Aristada |
| Avanir Pharmaceuticals, INC. | $80.74 | 2021-2022 | |
| Indivior INC. | $76.86 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $50.07 | 2021-2022 | |
| Novo Nordisk INC | $30.15 | 2025 | Wegovy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $24.13 | 2025 | |
| Ironshore Pharmaceuticals INC. | $13.72 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.61 | 2023 | Eliquis |
| Merck Sharp & Dohme LLC | $13.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archis Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.